

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Establishment of Our Company

Our Company was established as a limited liability company in the PRC on September 22, 2016 and was converted to a joint stock company with limited liability under the laws of the PRC with effect from January 30, 2026. As of the Latest Practicable Date, the registered capital of our Company was RMB28,824,452 divided into 288,244,520 Unlisted Shares with a nominal value of RMB0.10 each.

Our Company has established a principal place of business at 46/F, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong and has been registered with the Registrar of Companies in Hong Kong as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance on February 26, 2026. Ms. Chan Ching Nga (陳靜雅), one of our joint company secretaries, has been appointed as the authorized representative of our Company for the acceptance of service of process and notices on behalf of our Company in Hong Kong.

As our Company was established in the PRC, our corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in “Appendix V—Summary of Articles of Association” to this document.

2. Changes in the Share Capital of Our Company

As of the date of the establishment of our Company, our registered capital was RMB10,000,000. On January 30, 2026, our Company was converted into a joint stock company with limited liability under the laws of the PRC. Upon completion of such conversion, the registered capital of our Company was RMB28,824,452 divided into 288,244,520 Unlisted Shares with a nominal value of RMB0.10 each.

Save as disclosed in “History, Development and Corporate Structure”, there has been no other alteration in our share capital within the two years immediately preceding the date of this document.

3. Changes in the Share Capital of Our Subsidiaries

Details of our subsidiaries is set out in “History, Development and Corporate Structure—Our Principal Subsidiaries” and Note 1 to the Accountants’ Report as set out in Appendix I to this document.

On April 24, 2026, VivaVision Guangzhou was established as a limited company in the PRC with an initial registered capital of RMB5,000,000, and is a wholly-owned subsidiary of our Company.

Save as disclosed above, there has been no alteration in the share capital of the subsidiaries of our Company within two years immediately preceding the date of this document.

4. Restriction of Share Repurchase

For details of the restrictions on the share repurchase by our Company, see “Appendix V—Summary of Articles of Association” to this document.

5. Resolutions of Our Shareholders

At the extraordinary general meeting of our Company held on February 10, 2026, among other things, our Shareholders had resolved that:

- (a) the issue of H Shares with a nominal value of RMB0.1 each shall be approved and such H Shares shall be listed on the Stock Exchange;

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (b) the number of H Shares to be issued shall be no more than [REDACTED]% of the total issued share capital of our Company as enlarged by the [REDACTED] before the exercise of the [REDACTED];
- (c) subject to the filing with CSRC is completed, upon completion of the [REDACTED], [REDACTED] Unlisted Shares will be converted into H Shares on a one-for-one basis;
- (d) subject to the completion of the [REDACTED], the granting of a general mandate to the Board to allot and issue Shares at any time within a period up to the date of the conclusion of the next annual general meeting of the Shareholders or the date on which the Shareholders pass a resolution to revoke or change such mandate, whichever is earlier, provided that, the number of Shares to be issued or sold shall not exceed 20% of the number of the Shares in issue as at the date of Listing;
- (e) subject to the completion of the [REDACTED], the conditional adoption of the Articles of Association, which shall become effective on the Listing Date; and
- (f) our Board and/or its authorized person(s) have been authorized to handle all relevant matters relating to, among other things, the [REDACTED], the issue of H Shares and the Listing.

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

We have entered into the following contracts (not being contracts entered into in the ordinary course of business) within the two years preceding the date of this document that are or may be material:

- (a) the investment agreement dated November 29, 2024 entered into between the Company, Dr. Shen Wang (沈旺), Huzhou Xiulai Business Consulting Partnership (Limited Partnership) (湖州修暎商務諮詢合夥企業(有限合夥)), Wenzhou Renze Zhenhe Equity Investment Partnership Enterprise (Limited Partnership) (溫州仁澤真和股權投資合夥企業(有限合夥)) and The Innovation and Technology Venture Fund Corporation, pursuant to which Wenzhou Renze Zhenhe Equity Investment Partnership Enterprise (Limited Partnership) agreed to subscribe for increased registered capital of our Company of RMB78,957 at the consideration of RMB5 million and The Innovation and Technology Venture Fund Corporation agreed to subscribe for increased registered capital of our Company of RMB157,914 at the consideration of RMB10 million;
- (b) the investment agreement dated June 25, 2025 entered into between the Company, Dr. Shen Wang (沈旺), Huzhou Xiulai Business Consulting Partnership (Limited Partnership), Wenzhou Ouhai Xiangtou V-Capital Equity Investment Partnership Enterprise (Limited Partnership) (溫州甌海湘投一村股權投資合夥企業(有限合夥)), Zhejiang Yueke Xingwen Innovation and Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (浙江粵科興溫創新創業投資合夥企業(有限合夥)) and Tibet Longpan SME Development Fund Equity Investment Partnership (Limited Partnership) (西藏龍磐中小企業發展基金股權投資合夥企業(有限合夥)), pursuant to which (i) Wenzhou Ouhai Xiangtou V-Capital Equity Investment Partnership Enterprise (Limited Partnership) agreed to subscribe for increased registered capital of our Company of RMB947,482 at the consideration of RMB60 million; (ii) Zhejiang Yueke Xingwen Innovation and Entrepreneurship Investment Partnership Enterprise (Limited Partnership) agreed to subscribe for increased registered capital of our Company of RMB473,741 at the consideration of RMB30 million; and (iii) Tibet Longpan SME Development Fund Equity Investment Partnership (Limited Partnership) agreed to subscribe for increased registered capital of our Company of RMB473,741 at the consideration of RMB30 million;
- (c) the investment agreement dated November 14, 2025 entered into between the Company, Dr. Shen Wang (沈旺), Huzhou Xiulai Business Consulting Partnership (Limited Partnership), Guangzhou Kechuang Zhihui No. 4 Venture Capital

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- Partnership Enterprise (Limited Partnership) (廣州科創智匯四號創業投資合夥企業(有限合夥)) and Wenzhou Gongchuang Runmou Enterprise Management Consulting Partnership (Limited Partnership) (溫州市工創潤眸企業管理諮詢合夥企業(有限合夥)), pursuant to which (i) Guangzhou Kechuang Zhihui No. 4 Venture Capital Partnership Enterprise (Limited Partnership) agreed to subscribe for increased registered capital of our Company of RMB473,741 at the consideration of RMB30 million; and (ii) Wenzhou Gongchuang Runmou Enterprise Management Consulting Partnership (Limited Partnership) agreed to subscribe for increased registered capital of our Company of RMB157,914 at the consideration of RMB10 million;
- (d) the shareholders’ agreement dated November 14, 2025 entered into between our Company and the then shareholders of our Company, pursuant to which certain shareholders’ rights and obligations were agreed among the parties thereto;
- (e) a convertible bond agreement dated December 18, 2025 entered into between the Company and Wanlian Guangsheng Investment Co., Ltd. (萬聯廣生投資有限公司), pursuant to which Wanlian Guangsheng Investment Co., Ltd. agreed to provide a convertible loan to the Company in the principal amount of RMB7,000,000;
- (f) the termination agreement of the shareholders’ special rights dated February 10, 2026 entered into among the Company, WANG SHEN, Huzhou Xiulai Business Consulting Partnership (Limited Partnership) (湖州修暉商務諮詢合夥企業(有限合夥)), Magic Honor Holdings Limited, Weixuchen (Shanghai) Entrepreneurship Incubator Limited (維旭晨(上海)創業孵化器有限公司), Hangzhou Morning Spring Feihong Venture Capital Partnership Enterprise (Limited Partnership) (杭州曉池飛鴻創業投資合夥企業(有限合夥)), Hangzhou Qiandai Investment Management Partnership Enterprise (Limited Partnership) (杭州千岱投資管理合夥企業(有限合夥)), Xiamen Changchong No. 1 Investment Partnership Enterprise (Limited Partnership) (廈門長舂壹號投資合夥企業(有限合夥)), Beijing Longpan Health Medical Investment Center (L.P.) (北京龍磐健康醫療投資中心(有限合夥)), Hangzhou Beixin Venture Capital Partnership Enterprise (Limited Partnership) (杭州貝欣創業投資合夥企業(有限合夥)), Jingjiang Yingqi Investment Center (Limited Partnership) (靖江贏騏投資中心(有限合夥)), Suzhou Juming ZhongHong Fangren Venture Capital Partnership (L.P.) (蘇州聚明中泓方仁創業投資合夥企業(有限合夥)), Shanghai Weiqiandai Asset Management Partnership Enterprise (Limited Partnership) (上海維千岱資產管理合夥企業(有限合夥)), CR Biotech XI L.P., VVBI One Limited, Shenzhen Huawei Health Industry Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (深圳市華維健康產業創業投資合夥企業(有限合夥)), HSG Venture VIII Holdco K, Ltd., WELL ASPIRATIONS LIMITED, Suzhou Cenova Zekang Investment Center (Limited Partnership) (蘇州千驥澤康投資中心(有限合夥)), Shanghai Cenova Kangze Investment Center (Limited Partnership) (上海千驥康澤投資中心(有限合夥)), Yantai GTJA Huike Venture Capital Partnership Enterprise (Limited Partnership) (煙台高特佳匯科創業投資合夥企業(有限合夥)), Huzhou Weiyuan Enterprise Management Partnership (Limited Partnership) (湖州維遠企業管理合夥企業(有限合夥)), Shanghai Zhangjiang Torch Venture Investment Co., Ltd. (上海張江火炬創業投資有限公司), Ningbo CFS Venture Capital Partnership Enterprise (Limited Partnership) (寧波金策創業投資合夥企業(有限合夥)), Hangzhou Beiyi Equity Investment Fund Partnership Enterprise (Limited Partnership) (杭州貝奕股權投資基金合夥企業(有限合夥)), FENGHE VVB PTE. LTD., Xiamen Changrong Xuanhe Equity Investment Partnership Enterprise (Limited Partnership) (廈門長融烜赫股權投資合夥企業(有限合夥)), Yueshang (Jiaxing) Equity Investment Partnership (Limited Partnership) (越商(嘉興)股權投資合夥企業(有限合夥)), Yangzhou Shengze Equity Investment Partnership Enterprise (Limited Partnership) (揚州笙澤股權投資合夥企業(有限合夥)), Jiaxing Shengmou Equity Investment Partnership (Limited Partnership) (嘉興盛眸股權投資合夥企業(有限合夥)), Wenzhou Renze Zhenhe Equity Investment Partnership Enterprise (Limited Partnership) (溫州仁澤真和股權投資合夥企業(有限合夥)), Wenzhou V-Capital Medical and Health Industry Investment Partnership Enterprise (Limited Partnership) (溫州一村醫療健康產業投資合夥企業(有限合夥)), The Innovation and Technology Venture Fund Corporation, Zhejiang Yueke Xingwen Innovation and Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (浙江粵科興溫創新創業投資合夥企業(有限合夥)), Wenzhou Ouhai Xiangtou V-Capital Equity Investment Partnership Enterprise (Limited Partnership) (溫州甌海湘投一村

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

股權投資合夥企業(有限合夥)), Tibet Longpan SME Development Fund Equity Investment Partnership (Limited Partnership) (西藏龍磐中小企業發展基金股權投資合夥企業(有限合夥)), Guangzhou Kechuang Zhihui No. 4 Venture Capital Partnership (Limited Partnership) (廣州科創智匯四號創業投資合夥企業(有限合夥)), Wenzhou Gongchuang Runmou Enterprise Management Consulting Partnership (Limited Partnership) (溫州市工創潤眸企業管理諮詢合夥企業(有限合夥)) and Wanlian Guangsheng Investment Co., Ltd. (萬聯廣生投資有限公司), pursuant to which the termination and reinstatement of shareholders’ special rights were agreed among the aforementioned parties; and

(g) [REDACTED]

2. Intellectual Property Rights

(a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Date of Expiry
1..		42	Our Company	PRC	53666790	2031/12/06
2..	VIVAVISION	42	Our Company	PRC	53667895	2031/09/13
3..		5,10,42	Our Company	Hong Kong	307133986	2035/12/18
4..	VIVAVISION VIVAVISION	5,10,42	Our Company	Hong Kong	307133995	2035/12/18

(b) Patents

As of the Latest Practicable Date, we had registered the following patents which we consider to be or may be material to our business:

No.	Patent	Type	Registered Owner	Place of Registration	Patent Number	Date of Application	Date of Expiry
1..	Phosphorus-containing compound and preparation and use thereof (一種含磷化合物及其製備和應用)	Invention	Our Company	PRC	ZL201810291023.0	2018/04/03	2038/04/02
2..	An immune cell migration inhibitor (一種免疫細胞遷徙抑制劑)	Invention	Our Company	PRC	ZL201711050899.8	2017/10/31	2037/10/30
3..	A compound containing a five-membered ring and its preparation and applications (一種含五元環的化合物及其製備和應用)	Invention	Our Company	PRC	ZL201810455868.9	2018/05/14	2038/05/13

APPENDIX VI STATUTORY AND GENERAL INFORMATION

As of the Latest Practicable Date, we had applied for the following patents which we consider to be or may be material to our business:

No.	Patent	Type	Applicant	Place of Application	Application Number	Date of Application
1.	A VVN001-CONTAINING OPTHALMIC COMPOSITION (一種含VVN001的眼科組合物)	Invention	Our Company	PRC United States Europe Japan Korea Canada Singapore Hong Kong Israel	202310476403.2 18/718,308 23887181.8 2023-560923 10-2024-7022421 3,238,321 11202402955W 42024101206.1 312531	2023/04/27 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2024/12/20 2023/05/25
2.	OPHTHALMIC COMPOSITION FOR TREATING NON-INFECTIOUS INFLAMMATORY DISEASES (一種用於治療非感染性炎症疾病的眼科組合物)	Invention	Our Company	PRC United States Europe Japan Korea Canada Australia Singapore Hong Kong Israel Brazil India South Africa Eurasian Patent Organization	202310484101.X 18/693,334 23848463.8 2024-508982 10-2024-7024066 3,231,266 2023316921 11202400923R 42024101316.8 310946 BR112025023419-6 202527103481 2025/09504 202593048	2023/04/28 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2024/12/24 2023/05/25 2023/05/25 2023/05/25 2023/05/25 2023/05/25
3.	JAK inhibitors for treating inflammatory eye conditions	Invention	Our Company	International (WIPO)	PCT/CN2025/128136	2025/10/16
4.	A derivative of a JAK inhibitor (一種JAK抑制劑的衍生物)	Invention	Our Company	PRC World Intellectual Property Organization Taiwan	202510167836.9 PCT/CN2025/077333 115104259	2025/02/14 2025/02/14 2026/02/03
5.	INTRANASAL PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR FOR INFLAMMATORY UPPER RESPIRATORY DISEASE	Invention	Our Company	World Intellectual Property Organization	PCT/CN2026/086464	2026/03/27
6.	PRESERVATIVE-FREE OPTHALMIC COMPOSITIONS COMPRISING A TRICYCLIC JAK INHIBITOR AND THERAPEUTIC APPLICATIONS	Invention	Our Company	World Intellectual Property Organization	PCT/CN2026/096327	2026/05/12

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(c) *Domain name*

As of the Latest Practicable Date, our Group had registered the following domain name which we consider to be or may be material to our business:

No.	Domain name	Registered Owner	Date of Registration	Date of Expiry
1...	vivavisionbio.com	Our Company	2018/12/05	2026/12/05

C. FURTHER INFORMATION ABOUT DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interests

(a) *Directors and the chief executive of our Company*

As of the Latest Practicable Date, so far as our Directors are aware, Jiangxi Shining Weimou Pharmaceutical Co., Ltd. (江西閃亮維眸醫藥有限公司) is held as to 25.00% by our Company and approximately 15.00% by Shanghai Zhitong Jiurui Enterprise Management Partnership (Limited Partnership) (上海致同久瑞企業管理合夥企業(有限合夥)), which is held as to 40% by Dr. Xia Erning, our executive Director and chief technology officer, as its limited partner.

Save as disclosed above and in the section headed “Substantial Shareholders” in this document, immediately following the completion of the [REDACTED] and conversion of Unlisted Shares into H Shares, so far as our Directors are aware, none of our Directors or chief executive of our Company has any interests or short positions in the Shares, underlying Shares and debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO) or which will be required, under section 352 of the SFO, to be entered in the register referred to in that section, or which will be required, under the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules (the “Model Code”), to be notified to our Company and the Stock Exchange once the H Shares are listed.

(b) *Substantial Shareholders*

For the information on the persons who will, immediately following the completion of the [REDACTED], have interests or short positions in our Shares or underlying Shares which would be required to be disclosed to our Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the nominal value of any class of share capital carrying voting rights in all circumstances at general meetings of our Company, see “Substantial Shareholders” for details.

Save as disclosed in the section headed “Substantial Shareholders” in this document, our Directors are not aware of any persons (other than our Directors and chief executive) who will, immediately following the completion of the [REDACTED], have or be deemed or taken to have interests and/or short position in our Shares or underlying Shares which would be required to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any types of the issued voting shares of any member of our Group.

2. Service Contracts

Each of our Directors [has entered] into a service contract or a letter of appointment with our Company.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Save as disclosed above, we have not entered, and do not propose to enter, into any service contracts with any of our Directors in their respective capacities as Directors (other than contracts expiring or determinable by the employer within one year without any payment of compensation (other than statutory compensation)).

3. Directors’ Remuneration

Save as disclosed in “Directors and Senior Management” and Note 8 to “Appendix I—Accountants’ Report” for the financial years ended December 31, 2024 and 2025 and the six months ended June 30, 2026, none of our Directors received other remunerations of benefits in kind from us.

4. Disclaimers

Save as disclosed in this document:

- (a) none of our Directors or any of the parties listed in “—E. Other Information—4. Qualification and Consents of Experts” of this Appendix is:
 - (i) interested in our promotion, or in any assets which, within the two years immediately preceding the date of this document, have been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company; or
 - (ii) materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business;
- (b) save in connection with the [REDACTED] and the [REDACTED], none of our Directors or any of the parties listed in “—E. Other Information—4. Qualification and Consents of Experts” of this Appendix:
 - (i) is interested legally or beneficially in any shares in any member of our Group; or
 - (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of our Group;
- (c) none of our Directors or their close associates or any shareholders of our Company who to the knowledge of our Directors owns more than 5% of our issued share capital has any interest in our top five customers or suppliers; and
- (d) none of our Directors is a director or employee of a company that has an interest in the share capital of our Company which, once the H Shares are listed on the Hong Kong Stock Exchange, would have to be disclosed pursuant to Divisions 2 and 3 of Part XV of the SFO.

D. EMPLOYEE INCENTIVE SCHEME

To attract, incentivize and retain our employees and other eligible participants, and maintain the stability of our management team and talents, we established Huzhou Xiulai as our Employee Ownership Platform. See “History, Development and Corporate Structure—Employee Ownership Platform” for further details.

The following is a summary of the principal terms of the Employee Incentive Scheme. Under the Employee Incentive Scheme, Eligible Participants (as defined below) were granted partnership interests in the Employee Ownership Platform (“Awards”).

The Employee Incentive Scheme is not subject to the provisions of Chapter 17 of the Listing Rules as it does not involve any grant of share options or awards or any issuance of new Shares by our Company after Listing. Given the Shares under the Employee Incentive Scheme have already been issued to the Employee Ownership Platform as of the Latest Practicable Date, there will not be any dilutive effect to the issued Shares as a result of the operation of the Employee Incentive Scheme.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(a) Purposes

The purposes of the Employee Incentive Scheme is to incentivize our employees and other eligible participants to promote the further development of our Company.

(b) Eligible Participants

Eligible participants of the Employee Incentive Scheme (“Eligible Participants”) include Directors, mid-level management, core personnel and other employees of our Group, as well as external consultants and other personnel who are recognized by the Board as having made significant contributions to the Company. The list of Eligible Participants may be adjusted by Huzhou Xiulai from time to time.

(c) Administration

Huzhou Xiulai is responsible for administering the Employee Incentive Scheme, including but not limited to (i) determining and adjusting the list of Eligible Participants who are granted with Awards (the “Grantees”); (ii) determining the number and price of Awards to be granted; (iii) determining the repurchase arrangements of the Awards; (iv) amending the terms and conditions of the Awards; and (v) making all other decisions and determinations in relation to the Awards as deems necessary or advisable for the administration of the Employee Incentive Scheme.

(d) Shares under the Employee Incentive Scheme

As of the Latest Practicable Date, Huzhou Xiulai held 26,561,870 underlying Shares, representing approximately 9.22% of the issued share capital of our Company. Immediately upon completion of the [REDACTED] (assuming the [REDACTED] is not exercised), the Employee Ownership Platform will be interested in approximately [REDACTED]% of the total issued share capital of our Company.

As of date of this document, Huzhou Xiulai has [48] limited partners, among whom Dr. Xia Erning (夏爾寧) (our executive Director and chief technology officer) held approximately [12.96]% partnership interests as a limited partner therein. None of the limited partners of Huzhou Xiulai holds more than 30% of the partnership interests therein. The general partner of Huzhou Xiulai is Ms. Wu Ye (吳燁), the deputy director of human resources and administration of the Company.

No further Awards will be granted after the date of this document and the Employee Incentive Scheme will not cause any dilution of the shareholding of our Shareholders after the Listing.

(e) Lock-up, Repurchase and Transferability of Partnership Interests

The partnership interests held by the Grantees in the Employee Ownership Platform, which represent the Awards granted to the Grantees, are subject to lock-up restrictions: (i) for Grantees who are employees, the Awards are subject to a lock-up period of four years from the employment commencement date or such other date as specified in the relevant grant notice, with one-fourth being unlocked each year provided that the Grantee maintains a full-time employment relationship or service relationship with our Group; and (ii) for Grantees who are not employees, the Awards shall be unlocked upon the achievement of performance targets as specified in the relevant grant notice.

During the lock-up period, the Awards may be purchased by the general partner of Huzhou Xiulai or its designated entity in the event of, including but not limited to: (i) termination of the Grantee’s employment or service relationship with our Group without cause, in which case the locked award shall be transferred at the original subscription price, and the unlocked award shall, upon request by Huzhou Xiulai, be transferred at 50% of the net asset value per share based on the most recent financial statements submitted to the tax authorities at the time of repurchase; (ii) termination of the Grantee’s employment or service relationship with our Company for cause, in which case all partnership interests held by such Participant shall be transferred at the original subscription price; and (iii) death, serious illness, or loss of working capacity due to work-related injury of the Grantee, in which case the lawful heirs of such Participant shall be permitted to continue to hold the unlocked partnership interests directly or indirectly.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

After the [REDACTED], in addition to the restrictions under the Employee Incentive Scheme, the transfer or sale by the Grantees shall be subject to the lock-up requirements under the relevant laws and regulations and the rules of the Stock Exchange, or the respective agreements entered into between the Company and the relevant Grantees pursuant to the terms of the Employee Incentive Scheme (if applicable).

E. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to impose on our Company or our subsidiaries.

2. Litigation

Save as disclosed in this document, to the knowledge of our Directors, no member of our Group has significant litigation or claims pending or threatened against any member of our Group.

3. Sole Sponsor

The Sole Sponsor satisfies the independence criteria applicable to sponsor as set out in Rule 3A.07 of the Listing Rules.

The Sole Sponsor has made an application on behalf of our Company to the Stock Exchange for the listing of, and permission to deal in, the H Shares to be converted from Unlisted Shares and the H Shares to be issued pursuant to the [REDACTED]. The Sole Sponsor will receive a fee of US\$[700,000] for acting as the sponsor for the Listing.

4. Qualification and Consents of Experts

The qualifications of the experts who have given opinions or advice in this document are as follows:

Name	Qualification
China International Capital Corporation Hong Kong Securities Limited	Licensed to conduct Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 4 (advising on securities), Type 5 (advising on futures contracts) and Type 6 (advising on corporate finance) regulated activities under the SFO
Ernst & Young	Certified Public Accountants under Professional Accountant Ordinance (Chapter 50 of the Laws of Hong Kong) Registered Public Interest Entity Auditors under the Accounting and Financial Reporting Council Ordinance (Chapter 588 of the Laws of Hong Kong)
Global Law Office.	Legal advisers to our Company as to the PRC law
Global Law Office.	Legal advisers to our Company as to PRC intellectual property laws
Venture Partner, LLC. . . .	Legal advisers to our Company as to U.S. intellectual property laws
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. . .	Independent industry consultant

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Each of the experts has given and has not withdrawn its written consents to the issue of this document with the inclusion of its reports, letters, opinions or summaries of opinions (as the case may be) and the references to its names and logos included herein in the form and context in which it is respectively included.

As of the Latest Practicable Date, none of the experts named above has any of our shareholding interests in any member of our Group or rights (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for our securities in any member of our Group.

5. Compliance Adviser

Our Company has appointed Somerley Capital Limited as its Compliance Adviser in compliance with Rule 3A.19 of the Listing Rules.

6. Taxation of Holders of H Shares

Hong Kong stamp duty, currently charged at the ad valorem rate of 0.10% on the higher of the consideration for or the market value of the H Shares, will be payable by the purchaser on every purchase and by the seller on every sale of any Hong Kong securities, including H Shares (in other words, a total of 0.20% is currently payable on a typical sale and purchase transaction involving H Shares). In addition, a fixed stamp duty of HK\$5.00 is currently payable on any instrument of transfer of H Shares. Where one of the parties is a resident outside Hong Kong and does not pay the ad valorem duty due by it, the duty not paid will be assessed on the instrument of transfer (if any) and will be payable by the transferee. If no stamp duty is paid on or before the due date, a penalty of up to ten times the duty payable may be imposed.

7. Binding Effect

This document shall have the effect, if any application is made pursuant hereto, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

8. Bilingual document

The English language and Chinese language versions of this document are being published separately, in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

9. Promoters

The promoters of our Company comprised all of the 37 then shareholders of our Company before our conversion into a joint stock company with limited liability. Save as disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or benefits have been paid, allotted or given, or are proposed to be paid, allotted or given to the promoters named above in connection with the [REDACTED] or the related transactions described in this document.

10. Preliminary Expenses

Our Company did not incur any material preliminary expenses.

11. No Material Adverse Change

Our Directors confirm that, as of the date of this document, there has been no material adverse change in our financial or trading position or prospects since June 30, 2026 (being the date to which the latest audited consolidated financial statements of our Group were prepared).

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

12. Miscellaneous

- (a) within the two years immediately preceding the date of this document:
 - (i) save as disclosed in “History, Development and Corporate Structure” in this document, no share or loan capital of our Company or our subsidiaries had been issued or agreed to be issued or proposed to be fully or partly paid either for cash or for a consideration other than cash;
 - (ii) no share or loan capital of our Company or our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
 - (iii) save as disclosed in “[REDACTED]” in this document, no commissions, discounts, brokerages or other special terms have been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or our subsidiaries; and
 - (iv) save as disclosed in “[REDACTED]” in this document, no commission has been paid or is payable for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription of any share in our Company or our subsidiaries;
- (b) there are no founder, management or deferred shares nor any debentures in our Company or our subsidiaries;
- (c) there has not been any interruption in the business of our Group which may have or has had a significant effect on the financial position of our Group in the 12 months preceding the date of this document;
- (d) no company within our Group is presently listed on any stock exchange or traded on any trading system;
- (e) all necessary arrangements have been made to enable our H Shares to be admitted into CCASS for clearing and settlement;
- (f) our Company has no outstanding convertible debt securities or debentures;
- (g) there is no arrangement under which future dividends are waived or agreed to be waived, and there is no restriction affecting the remittance of profits or repatriation of capital by us into Hong Kong from outside Hong Kong; and
- (h) none of the equity and debt securities of our Company, if any, is listed or dealt with in any other stock exchange nor is any listing or permission to deal being or proposed to be sought.